BioCentury | Apr 30, 2007
Strategy

Scale was elusive

...major drugs in Ditropan XL for overactive bladder and Concerta extended release methylphenidate for ADHD. "Our Ditropan XL...
BioCentury | Apr 16, 2007
Clinical News

Ditropan XL oxybutynin regulatory update

...FDA proposed updating the precautions section of the label for JNJ's Ditropan oxybutynin to warn of...
...Ditropan, including 37 cases in children. JNJ said it is in the process of updating Ditropan's...
...pediatric exclusivity as mandated by Section 17 of the Best Pharmaceuticals for Children Act (BPCA). Ditropan...
BioCentury | May 29, 2006
Clinical News

Enablex darifenacin: Post-marketing study data

...each week of treatment. Data were presented at the American Urological Association meeting in Atlanta. Ditropan XL...
BioCentury | Apr 24, 2006
Product Development

Urge overkill

...Indevus/Esprit Sanctura trospium Oral muscarinic receptor antagonist; 20 mg twice daily Mkt Johnson & Johnson Ditropan XL...
BioCentury | Jun 7, 2004
Strategy

Deconstructing de-risking

...could get to $1 billion in revenues based on new formulations of marketed products including Ditropan XL...
BioCentury | Apr 12, 2004
Strategy

Hoping one deal begets even more

...sales director at Johnson & Johnson subsidiary Ortho-McNeil Pharmaceutical Inc. , where he worked on Ditropan XL...
...priority. Sanctura will compete with Detrol tolteridine from Pfizer Inc. (PFE, New York, N.Y.) and Ditropan...
BioCentury | May 19, 2003
Emerging Company Profile

Dynogen: Let the bladder beware

...of patients will suffer from disorders such as urinary incontinence. The few existing drugs include ditropan...
BioCentury | Jul 9, 2001
Clinical News

Ditropan XL oxybutynin chloride: Marketed

...Results from a U.S. post-marketing study of Ditropan XL in 14 patients with spinal cord injury and...
...of Ditropan XL in 40 adult patients with multiple sclerosis (MS), AZA said that patients given Ditropan XL...
...Product: Ditropan XL oxybutynin chloride Business: Urological Therapeutic category: Neurotransmission Target: Acetylcholine Description: Extended release formulation of oxybutynin chloride...
BioCentury | Jun 25, 2001
Clinical News

(S)-oxybutynin: Started Phase III trial

...with overactive bladder. (s)-oxybutynin is a chirally pure form of oxybutynin, the active ingredient in Ditropan...
BioCentury | Jun 20, 2001
Clinical News

Sepracor starts Phase III trials of (S)-oxybutynin

...with overactive bladder. (s)-Oxybutynin is a chirally pure form of oxybutynin, the active ingredient in Ditropan...
...which is marketed by Marion Labs to treat overactive bladder. Also, Alza (AZA) markets its Ditropan XL...
Items per page:
1 - 10 of 56